DK0489072T3 - Behandling af kronisk inflammatoriske tilstande - Google Patents

Behandling af kronisk inflammatoriske tilstande

Info

Publication number
DK0489072T3
DK0489072T3 DK90912793.8T DK90912793T DK0489072T3 DK 0489072 T3 DK0489072 T3 DK 0489072T3 DK 90912793 T DK90912793 T DK 90912793T DK 0489072 T3 DK0489072 T3 DK 0489072T3
Authority
DK
Denmark
Prior art keywords
treatment
chronic inflammatory
inflammatory conditions
patient
abnormally high
Prior art date
Application number
DK90912793.8T
Other languages
English (en)
Inventor
John Lawson Stanford
Graham Arthur William Rook
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of DK0489072T3 publication Critical patent/DK0489072T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)
  • Treatment Of Sludge (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK90912793.8T 1989-08-25 1990-08-24 Behandling af kronisk inflammatoriske tilstande DK0489072T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898919321A GB8919321D0 (en) 1989-08-25 1989-08-25 Treatment of chronic inflammatory conditions

Publications (1)

Publication Number Publication Date
DK0489072T3 true DK0489072T3 (da) 1996-04-15

Family

ID=10662094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90912793.8T DK0489072T3 (da) 1989-08-25 1990-08-24 Behandling af kronisk inflammatoriske tilstande

Country Status (13)

Country Link
US (1) US5833996A (da)
EP (1) EP0489072B1 (da)
JP (1) JP2987197B2 (da)
AT (1) ATE135588T1 (da)
AU (1) AU644813B2 (da)
CA (1) CA2065286C (da)
DE (1) DE69026094T2 (da)
DK (1) DK0489072T3 (da)
FI (1) FI920795A0 (da)
GB (2) GB8919321D0 (da)
NO (1) NO920722L (da)
WO (1) WO1991002542A1 (da)
ZA (1) ZA906753B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
ATE212378T1 (de) 1993-06-04 2002-02-15 Whitehead Biomedical Inst Stressproteine und ihre verwendung
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
US6406704B1 (en) 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6160093A (en) * 1996-08-29 2000-12-12 Genesis Researth And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
AUPO359396A0 (en) * 1996-11-13 1996-12-05 Amrad Operations Pty. Limited A method of treatment and pharmaceutical compositions useful for same
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
RU2197989C2 (ru) * 1996-12-18 2003-02-10 Стэнфорд Рук Лимитед ПРИМЕНЕНИЕ Mycobacterium vaccae ДЛЯ РЕГУЛЯЦИИ ПО ТИПУ ОТРИЦАТЕЛЬНОЙ ОБРАТНОЙ СВЯЗИ Th2-АКТИВНОСТИ ИММУННОЙ СИСТЕМЫ
US6878377B2 (en) 1996-12-18 2005-04-12 Stanford Rook Limited Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system
RU2135196C1 (ru) * 1996-12-19 1999-08-27 Научно-исследовательский институт по изучению лепры Способ иммунопрофилактики экспериментальной лепрозной инфекции
SI0971735T1 (sl) * 1997-04-01 2008-08-31 Borody Thomas J Postopek in sestavina za zdravljenje bolezni vnetja debelega äśrevesa
ATE231917T1 (de) 1997-08-05 2003-02-15 Stressgen Biotechnologies Corp Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
GB9723630D0 (en) * 1997-11-07 1998-01-07 Stanford Rook Ltd M.vaccae preparation and its use
RU2137137C1 (ru) * 1997-12-03 1999-09-10 Научно-исследовательский институт по изучению лепры Способ определения m.leprae у больных с регрессом заболевания
US6328978B1 (en) 1997-12-23 2001-12-11 Genesis Research & Development Corp. Ltd. Methods for the treatment of immunologically-mediated skin disorders
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
NZ505834A (en) * 1997-12-23 2002-12-20 Genesis Res & Dev Corp Ltd Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
US6497880B1 (en) 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
GB9903539D0 (en) 1999-02-16 1999-04-07 Stanford Rook Ltd Therapy using M.Vaccae
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
EP1196772A2 (en) 1999-07-08 2002-04-17 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
JP2003510335A (ja) * 1999-08-06 2003-03-18 コリクサ コーポレイション 自己免疫疾患の処置のためのワクチン
AU1814101A (en) 2000-01-14 2001-07-24 Massachusetts Institute Of Technology In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete ATP binding domain and is CD4+ cell-independent
IL153474A0 (en) 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
WO2002062959A2 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
GB0106987D0 (en) * 2001-03-20 2001-05-09 Stanford Rook Ltd Immunotherapeuitic agent
WO2003063759A2 (en) 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2487198A1 (fr) * 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
GB8917256D0 (en) * 1989-07-28 1989-09-13 Univ London Biological preparation and its use
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens

Also Published As

Publication number Publication date
EP0489072A1 (en) 1992-06-10
EP0489072B1 (en) 1996-03-20
US5833996A (en) 1998-11-10
ZA906753B (en) 1991-06-26
AU644813B2 (en) 1993-12-23
FI920795A7 (fi) 1992-02-24
GB8919321D0 (en) 1989-10-11
JP2987197B2 (ja) 1999-12-06
NO920722D0 (no) 1992-02-24
JPH05501870A (ja) 1993-04-08
FI920795A0 (fi) 1992-02-24
CA2065286C (en) 2000-05-16
DE69026094T2 (de) 1996-08-22
WO1991002542A1 (en) 1991-03-07
CA2065286A1 (en) 1991-02-26
GB2252044B (en) 1993-09-22
DE69026094D1 (de) 1996-04-25
NO920722L (no) 1992-04-24
ATE135588T1 (de) 1996-04-15
GB9203904D0 (en) 1992-04-15
GB2252044A (en) 1992-07-29
AU6289790A (en) 1991-04-03

Similar Documents

Publication Publication Date Title
FI920795A0 (fi) Behandling av kroniska inflammations- tillstaond.
ES2104731T3 (es) Micobacterium utilizado como adyuvante para antigenos.
ZA831817B (en) Sustained release therapeutic composition based on high molecular weight hydroxypropylmethylcellulose
NO20000413L (no) Karbamyloksyforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4
DE69905368D1 (en) Oxydiertes thymosin beta 4
TR199900656T2 (xx) �ndanonlar ile 262 ve 20S proteazomun engellenmesi.
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2001051008A3 (en) Selective activation of a th1 or th2 lymphocyte regulated immune response
IT8467250A1 (it) Copolimero alliloligosaccaride acrilico salificato, procedimento per la sua preparazione e suo impiego come superassorbente.
FR2348704A1 (fr) Procede de preparation d'un vaccin contre le virus de la rhinopneumonie equine et vaccin ainsi obtenu
DE68904382D1 (de) Schlagfesten kautschuk enthaltende schmelzklebstoffzusammensetzungen fuer die buchbinderei.
IT8520630A0 (it) Dispositivo di regolazione ortopedico per la mascella.
ES532286A0 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
CA2273848A1 (en) Mycobacterium vaccae for down-regulation of the th2 activity of the immune system
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
NO913499L (no) Analysefremgangsmaate for og behandling av autoimmunsykdommer.
Tritsch et al. Adenosine deaminase activity during the growth cycle of T and B lymphoid cell lines
Romagnani et al. Human Th1 and Th2 cells: Regulation of development and role in protection and disease
Bair et al. The diagnostic value of IgM to natural trisaccharide phenylpropionyl bovine serum albumin in leprosy patients: a preliminary report from Taiwan
IT8720060A0 (it) Perfluoro 2,3,4-trimetilpentano eprocedimento per la sua preparazione.
JPS5427390A (en) Bedstead device
FUKATA et al. Soybean Production on the Drained Paddy Field by Farmer's Group IV. Systematic use on the paddy field
Babich et al. Heat Treatment of Railroad Rails
ES2120883A1 (es) Nuevo fondo para la fotografia intraoral aplicable en odontoestomatologia.
ES1019467Y (es) Colector publico para pilas desechables.